Verastem Stock Today
| VSTM Stock | USD 4.00 0.07 1.78% |
Performance11 of 100
| Odds Of DistressOver 67
|
Verastem is selling at 4.00 as of the 24th of November 2024; that is 1.78 percent increase since the beginning of the trading day. The stock's lowest day price was 3.81. Verastem has more than 67 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. Equity ratings for Verastem are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of October 2024 and ending today, the 24th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of January 2012 | Category Healthcare | Classification Health Care |
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts. Verastem operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 44.51 M outstanding shares of which 2.46 M shares are at this time shorted by private and institutional investors with about 2.31 trading days to cover. More on Verastem
Moving against Verastem Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Verastem Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Daniel Paterson | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVerastem can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Verastem's financial leverage. It provides some insight into what part of Verastem's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Verastem (VSTM) is traded on NASDAQ Exchange in USA. It is located in 117 Kendrick Street, Needham, MA, United States, 02494 and employs 73 people. Verastem is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 178.03 M. Verastem conducts business under Biotechnology sector and is part of Health Care industry. The entity has 44.51 M outstanding shares of which 2.46 M shares are at this time shorted by private and institutional investors with about 2.31 trading days to cover.
Verastem currently holds about 94.31 M in cash with (86.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5.
Check Verastem Probability Of Bankruptcy
Ownership AllocationVerastem shows a total of 44.51 Million outstanding shares. Over half of Verastem's outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Verastem Ownership Details
Verastem Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs O'connor Llc | 2024-09-30 | 430.7 K | |
| Affinity Asset Advisors, Llc | 2024-09-30 | 400 K | |
| State Street Corp | 2024-06-30 | 359 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 332.4 K | |
| Northern Trust Corp | 2024-09-30 | 286.6 K | |
| Tang Capital Management Llc | 2024-09-30 | 270 K | |
| Sio Capital Management, Llc | 2024-09-30 | 133.4 K | |
| Dafna Capital Management Llc | 2024-09-30 | 127.7 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 103.6 K | |
| Nantahala Capital Management, Llc | 2024-09-30 | 3.7 M | |
| Vanguard Group Inc | 2024-09-30 | 1.9 M |
Verastem Historical Income Statement
Verastem Stock Against Markets
Verastem Corporate Management
| Jonathan Pachter | Chief Officer | Profile | |
| Michael Crowther | Chief Officer | Profile | |
| Sean Flynn | Gen VP | Profile | |
| MD MSc | Head Strategy | Profile | |
| Robert Weinberg | CoFounder Board | Profile | |
| Daniel Calkins | Interim Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verastem. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verastem. If investors know Verastem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verastem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.14) | Revenue Per Share 0.331 | Quarterly Revenue Growth (1.00) | Return On Assets (0.47) | Return On Equity (1.37) |
The market value of Verastem is measured differently than its book value, which is the value of Verastem that is recorded on the company's balance sheet. Investors also form their own opinion of Verastem's value that differs from its market value or its book value, called intrinsic value, which is Verastem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verastem's market value can be influenced by many factors that don't directly affect Verastem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verastem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.